Hypoglycemic Events

Hypoglycemic events are episodes in which blood glucose falls below the level needed to support normal physiological and cognitive function, making them important in diabetes care and behavioral research. Low glucose activates counterregulatory responses, including the release of glucagon and epinephrine, which can produce sweating, tremor, hunger, irritability, confusion, and changes in attention or decision-making. These behavioral and cognitive effects may alter everyday activities, medication management, and responses to environmental demands, while severe episodes can impair consciousness. Studying hypoglycemic events helps researchers characterize symptom recognition, adaptive behavior, safety risks, and strategies for preventing recurrent low-blood-glucose episodes.

Hypoglycemic Events - Related Videos

Education

JoVE Core - Pharmacology

Oral Hypoglycemic Agents: Glinides

0 Views •

2024

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: Sulfonylureas

0 Views •

2024

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

Oral Hypoglycemic Agents: Biguanides and Glitazones

0 Views •

2024

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Research

JoVE Journal - Medicine

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

0 Views •

Cited by 4 •

2024

A hyperglycemic clamp is used for measuring insulin release with a maintained higher blood glucose concentration. A hypoglycemic clamp is for measuring glucose production induced by counter-regulatory responses. Both methods use the same surgical procedure. Here, we present a clamp technique to assess systemic glucose metabolism.

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

0 Views •

2024

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells. Acarbose and miglitol are typically...

View All Results

FAQs

Related Topics